- Home
- BCAB vs SCYX Comparison
BCAB vs SCYX Comparison
Compare BCAB & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BCAB | SCYX |
|---|---|---|
| Founded | 2007 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.6M | 26.3M |
| IPO Year | 2020 | 2014 |
Fundamental Metrics
Financial Performance| Metric | BCAB | SCYX |
|---|---|---|
| Price | $0.73 | $0.60 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $1.00 | ★ $3.00 |
| AVG Volume (30 Days) | ★ 1.1M | 366.6K |
| Earning Date | 11-13-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $2,932,000.00 |
| Revenue This Year | N/A | $167.73 |
| Revenue Next Year | N/A | $290.78 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.24 | $0.57 |
| 52 Week High | $1.43 | $1.49 |
Technical Indicators
Market Signals| Indicator | BCAB | SCYX |
|---|---|---|
| Relative Strength Index (RSI) | 44.92 | 33.43 |
| Support Level | $0.63 | $0.58 |
| Resistance Level | $0.83 | $0.63 |
| Average True Range (ATR) | 0.08 | 0.02 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 37.10 | 18.76 |
Price Performance
Historical ComparisonAbout BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.
About SCYX SCYNEXIS Inc.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.